Diabetes Obes Metab: Prevalence and progression of chronic kidney disease in patients with type 2 diabetes

Diabetes is the most common cause of chronic kidney disease (CKD), and it is reported that the prevalence of CKD in diabetic patients is as high as 40%.

Recently, Diabetes Obesity & Metabolism, an authoritative journal in the field of metabolic endocrine diseases, published a research article on this global, 3-year prospective observational study of the initiation of second-line hypoglycemic therapy for patients with type 2 diabetes (T2D) Researchers aim to report changes in the prevalence and severity of chronic kidney disease (CKD).

Researchers define CKD staging based on estimated glomerular filtration rate (eGFR).
In total, the researchers measured baseline serum creatinine levels in 7,743 patients from 35 countries/regions.

Among the subjects in this study, males accounted for 56.
7%; the average age was 58.
1 years; the average eGFR was 87.
5μmL/min/1.
73m2.
For patients with CKD stages 0-1, 2, 3, and 4-5, the baseline disease The estimated values ​​of the rate are 51.
4%, 37.
7%, 9.
4% and 1.
4%, respectively.
A total of 5819 (74.
2%) patients in the study had at least one follow-up measurement of serum creatinine (median time between two measurements was 2.
9 years, interquartile range was 1.
9-3.
0 years).
During follow-up, the average eGFR dropped slightly to 85.
7 8mL/min/1.
73m2.
15.
7% of patients had progression of CKD (increased by more than 1 stage), and 12% of patients had a decreased CKD stage (decreased by more than 1 stage).

In short, after the start of second-line treatment, a considerable number of T2D patients developed CKD or developed CKD progression.
These patients should regularly monitor renal function to ensure early diagnosis and treatment of CKD .

 
Original source:
 
Kamlesh Khunti.